Gossamer Bio Inc (GOSS) 13F Positioning & Ownership Changes (Q2 2026)

GOSS ranks #3368 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

GOSS is a disclosed holding of David Shaw (D. E. Shaw & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

GOSS is a top-conviction position for Worth Venture Partners, LLC — at 9.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in GOSS belongs to D. E. Shaw & Co., Inc., but the position matters far more to Worth Venture Partners, LLC, who has 9.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

IFP Advisors, Inc has trimmed its GOSS position for two straight quarters, cutting it by $1.9K while still holding $14.0.

GOSS is down 1.3% today, but institutions show net buying of $34.2M this quarter — a divergence between today's price move and the underlying institutional flow.

GOSS reported a net loss of $125.2M over the trailing twelve months.

• Not yet profitable — net loss of $125.2M over the trailing twelve months
• Revenue grew 32.4% year over year
• Net income improved year over year, from -$138.7M to -$125.2M
• Operating cash flow was negative, using $171.3M in cash
• Current ratio of 2.64x — enough short-term assets to cover short-term liabilities
• Total liabilities currently exceed total assets (negative shareholder equity)